Contractor
OREXO US INC
MORRISTOWN, NJ
- UEI
- MN1MPMBCVVD5
- Parent UEI
- G3NJFQBBMP39
- Resolved by
- uei
- Confidence
- 1.000
Obligated to date
$11,450,7121
Awards
2
Agencies served
2
Active from Jun 13, 2016 to Sep 4, 2026.
Sign in to watchRecent awards
| Award | Agency | Place | First action | Current value |
|---|---|---|---|---|
| 75A50125C00010 CLINICAL DEVELOPMENT OF OX390 (ATIPAMEZOLE) AS AN ?2 AGONIST REVERSAL AGENT FOR HUMAN USE TO COUNTERACT THE SEDATIVE EFFECTS OF XYLAZINE, MEDETOMIDINE, AND OTHER ?2 AGONISTS | Department of Health and Human Services | NJ | Sep 24, 2025 | $11,450,712 |
| V797D60656 65 I B, DRUGS, PHARMACEUTICALS,&HEMATOLOGY RELATED PRODUCT FSS CONTRACT AWARD | Department of Veterans Affairs | — | Jun 13, 2016 | — |
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.
- 1Awards are attributed by Unique Entity Identifier MN1MPMBCVVD5, the government's own recipient identifier, not by name matching.
- 2Award records from USAspending.gov, last refreshed Sep 12, 2026.